Tenax Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Tenax Therapeutics Reports Increased R&D Spending Amidst Phase 3 Levosimendan Program Advancement
Tenax Therapeutics' 10-K filing reveals a significant increase in research and development expenses as the company progresses with its Phase 3 clinical trial for oral levosimendan.
NASDAQ
Tenax Therapeutics' 10-K filing details its capital structure, recent reverse stock splits, and strategic focus on advancing its levosimendan program.